Skip to main content
SpringerLink
Log in

Primary Cutaneous and Systemic CD30+ T-cell Lymphoproliferative Disorders

  • Chapter
  • First Online:
T-Cell Lymphomas

Part of the book series: Contemporary Hematology ((CH))

  • 1264 Accesses

Abstract

The CD30 positive malignancies comprise a spectrum of both benign and malignant diseases. Primary cutaneous anaplastic large-cell lymphomas and lymphomatoid papulosis are the most common cutaneous entities and are restricted to the cutaneous compartment. There is significant clinical and histopathologic overlap between these entities and both have an excellent prognosis. The systemic anaplastic large-cell lymphomas are further characterized by expression of the ALK protein, with ALK positive variants having a much better outcome after chemotherapy than systemic ALK negative disease. Novel therapeutic approaches include CD30-targeted agents such as monoclonal antibodies and the CD30 fusion protein, brentuximab vedotin.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Schwab U, Stein H, Gerdes J, et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin’s disease and a subset of normal lymphoid cells. Nature. 1982;299:65–7.

    Article  PubMed  CAS  Google Scholar 

  2. Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin’s disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood. 1985;66:848–58.

    PubMed  CAS  Google Scholar 

  3. Durkop H, Latza U, Hummel M, Eitelbach F, Seed B, Stein H. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin’s disease. Cell. 1992;68:421–7.

    Article  PubMed  CAS  Google Scholar 

  4. Mir SS, Richter BW, Duckett CS. Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells. Blood. 2000;96:4307–12.

    PubMed  CAS  Google Scholar 

  5. Kadin ME. Common activated helper-T-cell origin for lymphomatoid papulosis, mycosis fungoides, and some types of Hodgkin’s disease. Lancet. 1985;2:864–5.

    Article  PubMed  CAS  Google Scholar 

  6. Kadin ME, Sako D, Berliner N, et al. Childhood Ki-1 lymphoma presenting with skin lesions and peripheral lymphadenopathy. Blood. 1986;68:1042–9.

    PubMed  CAS  Google Scholar 

  7. Rimokh R, Magaud JP, Berger F, et al. A translocation involving a specific breakpoint (q35) on chromosome 5 is characteristic of anaplastic large cell lymphoma (‘Ki-1 lymphoma’). Br J Haematol. 1989;71:31–6.

    Article  PubMed  CAS  Google Scholar 

  8. Le Beau MM, Bitter MA, Larson RA, et al. The t(2;5)(p23;q35): a recurring chromosomal abnormality in Ki-1-positive anaplastic large cell lymphoma. Leukemia. 1989;3:866–70.

    PubMed  Google Scholar 

  9. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science. 1994;263:1281–4.

    Article  PubMed  CAS  Google Scholar 

  10. Shiota M, Nakamura S, Ichinohasama R, et al. Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. Blood. 1995;86:1954–60.

    PubMed  CAS  Google Scholar 

  11. Pulford K, Lamant L, Morris SW, et al. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood. 1997;89:1394–404.

    PubMed  CAS  Google Scholar 

  12. Savage KJ, Harris NL, Vose JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008;111:5496–504.

    Article  PubMed  CAS  Google Scholar 

  13. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105:3768–85.

    Article  PubMed  CAS  Google Scholar 

  14. Macaulay WL. Lymphomatoid papulosis. A continuing self-healing eruption, clinically benign–histologically malignant. Arch Dermatol. 1968;97:23–30.

    Article  PubMed  CAS  Google Scholar 

  15. Bekkenk MW, Geelen FA, van Voorst Vader PC, et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood. 2000;95:3653–61.

    PubMed  CAS  Google Scholar 

  16. Liu HL, Hoppe RT, Kohler S, Harvell JD, Reddy S, Kim YH. CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. J Am Acad Dermatol. 2003;49:1049–58.

    Article  PubMed  Google Scholar 

  17. Wang HH, Myers T, Lach LJ, Hsieh CC, Kadin ME. Increased risk of lymphoid and nonlymphoid malignancies in patients with lymphomatoid papulosis. Cancer. 1999;86:1240–5.

    Article  PubMed  CAS  Google Scholar 

  18. Kadin ME. Primary Ki-1-positive anaplastic large-cell lymphoma: a distinct clinicopathologic entity. Ann Oncol. 1994;5 Suppl 1:25–30.

    PubMed  Google Scholar 

  19. Le Deley MC, Reiter A, Williams D, et al. Prognostic factors in childhood anaplastic large cell lymphoma: results of a large European intergroup study. Blood. 2008;111:1560–6.

    Article  PubMed  Google Scholar 

  20. de Bruin PC, Beljaards RC, van Heerde P, et al. Differences in clinical behaviour and immunophenotype between primary cutaneous and primary nodal anaplastic large cell lymphoma of T-cell or null cell phenotype. Histopathology. 1993;23:127–35.

    Article  PubMed  Google Scholar 

  21. Franchina M, Kadin ME, Abraham LJ. Polymorphism of the CD30 promoter microsatellite repressive element is associated with development of primary cutaneous lymphoproliferative disorders. Cancer Epidemiol Biomarkers Prev. 2005;14:1322–5.

    Article  PubMed  CAS  Google Scholar 

  22. Nijsten T, Curiel-Lewandrowski C, Kadin ME. Lymphomatoid papulosis in children: a retrospective cohort study of 35 cases. Arch Dermatol. 2004;140:306–12.

    Article  PubMed  Google Scholar 

  23. Fletcher CL, Orchard GE, Hubbard V, Whittaker SJ, Edelson RL, Russell-Jones R. CD30(+) cutaneous lymphoma in association with atopic eczema. Arch Dermatol. 2004;140:449–54.

    Article  PubMed  Google Scholar 

  24. Beljaards RC, Willemze R. The prognosis of patients with lymphomatoid papulosis associated with malignant lymphomas. Br J Dermatol. 1992;126:596–602.

    Article  PubMed  CAS  Google Scholar 

  25. Basarab T, Fraser-Andrews EA, Orchard G, Whittaker S, Russel-Jones R. Lymphomatoid papulosis in association with mycosis fungoides: a study of 15 cases. Br J Dermatol. 1998;139:630–8.

    Article  PubMed  CAS  Google Scholar 

  26. Chott A, Vonderheid EC, Olbricht S, Miao NN, Balk SP, Kadin ME. The dominant T cell clone is present in multiple regressing skin lesions and associated T cell lymphomas of patients with lymphomatoid papulosis. J Invest Dermatol. 1996;106:696–700.

    Article  PubMed  CAS  Google Scholar 

  27. Wang HH, Lach L, Kadin ME. Epidemiology of lymphomatoid papulosis. Cancer. 1992;70:2951–7.

    Article  PubMed  CAS  Google Scholar 

  28. Schiemann WP, Pfeifer WM, Levi E, Kadin ME, Lodish HF. A deletion in the gene for transforming growth factor beta type I receptor abolishes growth regulation by transforming growth factor beta in a cutaneous T-cell lymphoma. Blood. 1999;94:2854–61.

    PubMed  CAS  Google Scholar 

  29. Vonderheid EC, Sajjadian A, Kadin ME. Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders. J Am Acad Dermatol. 1996; 34:470–81.

    Article  PubMed  CAS  Google Scholar 

  30. Yagi H, Tokura Y, Furukawa F, Takigawa M. Th2 cytokine mRNA expression in primary cutaneous CD30-positive lymphoproliferative disorders: successful treatment with recombinant interferon-gamma. J Invest Dermatol. 1996;107:827–32.

    Article  PubMed  CAS  Google Scholar 

  31. Schmuth M, Topar G, Illersperger B, Kowald E, Fritsch PO, Sepp NT. Therapeutic use of interferon-alpha for lymphomatoid papulosis. Cancer. 2000;89:1603–10.

    Article  PubMed  CAS  Google Scholar 

  32. Krathen RA, Ward S, Duvic M. Bexarotene is a new treatment option for lymphomatoid papulosis. Dermatology. 2003;206:142–7.

    Article  PubMed  CAS  Google Scholar 

  33. Drews R, Samel A, Kadin ME. Lymphomatoid papulosis and anaplastic large cell lymphomas of the skin. Semin Cutan Med Surg. 2000;19:109–17.

    Article  PubMed  CAS  Google Scholar 

  34. Willemze R, Beljaards RC. Spectrum of primary cutaneous CD30 (Ki-1)-positive lymphoproliferative disorders. A proposal for classification and guidelines for management and treatment. J Am Acad Dermatol. 1993;28:973–80.

    Article  PubMed  CAS  Google Scholar 

  35. Beljaards RC, Kaudewitz P, Berti E, et al. Primary cutaneous CD30-positive large cell lymphoma: definition of a new type of cutaneous lymphoma with a favorable prognosis. A European Multicenter Study of 47 patients. Cancer. 1993;71:2097–104.

    Article  PubMed  CAS  Google Scholar 

  36. Paulli M, Berti E, Rosso R, et al. CD30/Ki-1-positive lymphoproliferative disorders of the skin–clinicopathologic correlation and statistical analysis of 86 cases: a multicentric study from the European Organization for Research and Treatment of Cancer Cutaneous Lymphoma Project Group. J Clin Oncol. 1995;13:1343–54.

    PubMed  CAS  Google Scholar 

  37. Brice P, Cazals D, Mounier N, et al. Primary cutaneous large-cell lymphoma: analysis of 49 patients included in the LNH87 prospective trial of polychemotherapy for high-grade lymphomas. Groupe d’Etude des Lymphomes de l’Adulte. Leukemia. 1998;12:213–9.

    Article  PubMed  CAS  Google Scholar 

  38. Rijlaarsdam JU, Huijgens PC, Beljaards RC, Bakels V, Willemze R. Oral etoposide in the treatment of cutaneous large-cell lymphomas. A preliminary report of four cases. Br J Dermatol. 1992;127:524–8.

    Article  PubMed  CAS  Google Scholar 

  39. The International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124–30.

    Article  Google Scholar 

  40. Falini B, Pileri S, Zinzani PL, et al. ALK+ lymphoma: clinico-pathological findings and outcome. Blood. 1999;93:2697–706.

    PubMed  CAS  Google Scholar 

  41. de Jong D, Vasmel WL, de Boer JP, et al. Anaplastic large-cell lymphoma in women with breast implants. JAMA. 2008;300:2030–5.

    Article  PubMed  Google Scholar 

  42. Gascoyne RD, Aoun P, Wu D, et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood. 1999;93:3913–21.

    PubMed  CAS  Google Scholar 

  43. Suzuki R, Kagami Y, Takeuchi K, et al. Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype. Blood. 2000;96:2993–3000.

    PubMed  CAS  Google Scholar 

  44. Benharroch D, Meguerian-Bedoyan Z, Lamant L, et al. ALK-positive lymphoma: a single disease with a broad spectrum of morphology. Blood. 1998;91:2076–84.

    PubMed  CAS  Google Scholar 

  45. Stein H, Foss HD, Durkop H, et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000;96:3681–95.

    PubMed  CAS  Google Scholar 

  46. Delsol G, Falini B, Muller-Hermelink HK, et al. Anaplastic large cell lymphoma (ALCL), ALK-positive in WHO Classification of Tumors of haematopoietic and Lymphoid Tissues. 4th ed. Lyon: WHO PRESS; 2008.

    Google Scholar 

  47. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science. 1995;267:316–7.

    PubMed  CAS  Google Scholar 

  48. Tilly H, Gaulard P, Lepage E, et al. Primary anaplastic large-cell lymphoma in adults: clinical presentation, immunophenotype, and outcome. Blood. 1997;90:3727–34.

    PubMed  CAS  Google Scholar 

  49. Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood. 2004;104:626–33.

    Article  PubMed  CAS  Google Scholar 

  50. Le Gouill S, Milpied N, Buzyn A, et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. J Clin Oncol. 2008;26:2264–71.

    Article  PubMed  Google Scholar 

  51. Schmitz N, Trumper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010;116:3418–25.

    Article  PubMed  CAS  Google Scholar 

  52. Song KW, Mollee P, Keating A, Crump M. Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype. Br J Haematol. 2003;120:978–85.

    Article  PubMed  Google Scholar 

  53. Fanin R, Ruiz de Elvira MC, Sperotto A, Baccarani M, Goldstone A. Autologous stem cell transplantation for T and null cell CD30-positive anaplastic large cell lymphoma: analysis of 64 adult and paediatric cases reported to the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 1999;23:437–42.

    Article  PubMed  CAS  Google Scholar 

  54. Whittaker SJ, Demierre MF, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010;28:4485–91.

    Article  PubMed  CAS  Google Scholar 

  55. Nickelsen M, Ziepert M, Zeynalova S, et al. High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Ann Oncol. 2009;20:1977–84.

    Article  PubMed  CAS  Google Scholar 

  56. Corradini P, Cavo M, Lokhorst H, et al. Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood. 2003;102:1927–9.

    Article  PubMed  CAS  Google Scholar 

  57. Dodero A, Spina F, Narni F, et al. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. Leukemia. 2012;26:520–6.

    Article  PubMed  CAS  Google Scholar 

  58. O’Connor OA, Horwitz S, Hamlin P, et al. Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol. 2009;27:4357–64.

    Article  PubMed  Google Scholar 

  59. Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25:3109–15.

    Article  PubMed  CAS  Google Scholar 

  60. Dang NH, Pro B, Hagemeister FB, et al. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br J Haematol. 2007;136:439–447.

    Article  PubMed  CAS  Google Scholar 

  61. Coiffier B, Pro B, Prince HM, et al. Final results from a pivotal, multicenter, international, open-label, phase 2 study of romidepsin in progressive or relapsed peripheral T-cell lymphoma (PTCL) following prior systemic therapy. Blood (ASH Annual Meeting Abstracts). 2010;116:114.

    Google Scholar 

  62. Piekarz R WJ, Frye R, et al. Results of a phase 2 NCI multicenter study of romidepsin in patients with relapsed peripheral T-cell lymphoma (PTCL). ASH Annual Meeting Abstracts. 2008;1567.

    Google Scholar 

  63. Damaj G, Bouabdallah R, Vey N, Bilger K, Mohty M, Gastaut JA. Single-agent thalidomide induces response in T-cell lymphoma. Eur J Haematol. 2005;74:169–71.

    Article  PubMed  CAS  Google Scholar 

  64. Dueck GS CN, Prasad A et al. Activity of lenalidomide in a phase II trial for T-cell lymphoma: report on the first 24 cases. ASCO Annual Meeting; 2009:8524.

    Google Scholar 

  65. Borchmann P, Treml JF, Hansen H, et al. The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma. Blood. 2003;102:3737–42.

    Article  PubMed  CAS  Google Scholar 

  66. Ansell SM, Horwitz SM, Engert A, et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin’s lymphoma and anaplastic large-cell lymphoma. J Clin Oncol. 2007;25:2764–9.

    Article  PubMed  CAS  Google Scholar 

  67. Forero-Torres A, Leonard JP, Younes A, et al. A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol. 2009;146:171–9.

    Article  PubMed  CAS  Google Scholar 

  68. Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102:1458–65.

    Article  PubMed  CAS  Google Scholar 

  69. Duvic M, Reddy SA, Pinter-Brown L, et al. A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders. Clin Cancer Res. 2009;15:6217–24.

    Article  PubMed  CAS  Google Scholar 

  70. Younes A F-TA, Bartlett NL. Multiple complete responses in a phase I dose-escalation study of the antibody-drug conjugate SGN-35 in patients with relapsed or refractory CD-30 positive lymphomas. ASH Annual Meeting Abstracts; 2008.

    Google Scholar 

  71. Bartlett NL F-TA, Rosenblatt JD. Complete remissions with weekly dosing of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in a phase I dose-escalation study in patients with relapsed or refractory Hodgkin Lymphoma (HL) or systemic anaplastic large cell lymphoma. ASCO Annual Meeting Abstracts; 2009:8500.

    Google Scholar 

  72. Pro B, Advani R, Brice P, Bartlett N, Rosenblatt J, et al. Durable remissions with brentuximab vedotin (SGN-35): updated results of a phase II study in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL). J Clin Oncol. 2011;29:9032.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology and Skin Surgery, Boston University of Medicine and Roger Williams Medical Center, Providence, RI, USA

    Marshall E. Kadin

  2. Department of Medical Oncology/Hematology, Yale University School of Medicine, 333 Cedar Street, FMP 130, 208032, New Haven, CT, 06520, USA

    Francine Foss

Authors
  1. Marshall E. Kadin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francine Foss
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francine Foss .

Editor information

Editors and Affiliations

  1. Yale University School of Medicine, Dept. of Medical Oncology/Hematology, Cedar Street 333, New Haven, 06520, Connecticut, USA

    Francine Foss

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Kadin, M.E., Foss, F. (2013). Primary Cutaneous and Systemic CD30+ T-cell Lymphoproliferative Disorders. In: Foss, F. (eds) T-Cell Lymphomas. Contemporary Hematology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-170-7_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-62703-170-7_5

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-62703-169-1

  • Online ISBN: 978-1-62703-170-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation